Germany's Merck open to more M&A for its Life Science division
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 17 2024
0mins
Source: Reuters
Acquisition Plans: Merck is open to further acquisitions in its Life Science business following the announcement of its $600 million purchase of Mirus Bio, with a focus on finding the right targets at the right time and price.
Business Outlook Adjustments: The company has adjusted its growth expectations for its Life Science and Healthcare divisions while raising its mid-term outlook for the electronics sector due to increased demand for AI-related chips.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
